sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets

Registration

Registration

NCT07850765

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

1260

Start

2026-08-28

Primary completion

2026-08-31

Lead sponsor

Novo Nordisk A/S

Conditions

Overweight; Obesity

Interventions

DRUG:Semaglutide

Results posted

FALSE

Individual participant data sharing

YES

Registered primary outcomes

• Change in Food Noise Questionnaire (FNQ) score [At data capture (Day 1)]
• Change in Body Weight [At data capture (Day 1)]
• Health-Related Quality of Life Measured by EQ-5D-5L [At data capture (Day 1)]
• Health Status Measured by EQ Visual Analogue Scale (EQ-VAS) [At data capture (Day 1)]
• Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ) [At data capture (Day 1)]
• Number of Participant Satisfaction With Wegovy [At data capture (Day 1)]
• Change in Body Mass Index (BMI) [At data capture (Day 1)]
• Percent Change in Body Weight [At data capture (Day 1)]
• Number of Participants with Achievement of Weight-Loss Target [At data capture (Day 1)]
• Number of Participants who Concern About Future Weight Gain [At data capture (Day 1)]
• Impact of Wegovy on Weight-Related Burden [At data capture (Day 1)]
• Impact of Wegovy on Daily Life and Health Behaviours [At data capture (Day 1)]